| Name | Title | Contact Details |
|---|
Johnson & Johnson is a multinational healthcare company founded in 1886 in New Brunswick, New Jersey. The company is dedicated to improving human health and well-being through its innovative products and services. Johnson & Johnson operates in three main segments. The Consumer Health segment includes popular brands like Band-Aids, Tylenol, and Johnsons baby products, offering a variety of personal care and over-the-counter medications. The Pharmaceuticals division develops prescription drugs across therapeutic areas such as immunology, infectious diseases, and oncology. Lastly, the Medical Devices segment focuses on creating and manufacturing devices and diagnostics for surgical procedures, orthopedics, and vision care. The companys products cater to a wide audience, including consumers, healthcare professionals, and medical institutions, ensuring accessibility and support for various health needs.
ParetoHealth is a healthcare benefits solutions provider focused on midsize employers with 50 to 1,000 employees. The company aims to reduce healthcare cost volatility and improve financial outcomes through innovative self-insurance models. It has established itself as the largest health benefits captive in the U.S., managing over $6.6 billion in healthcare spending and serving more than 3,000 employers, which collectively cover over 1 million lives. The company offers a range of services, including its Risk Shield program, which provides a shared-risk model for predictable costs and stop-loss protection against large claims. Its Savings Engine utilizes data analytics and clinical expertise to manage medical costs and improve pharmacy solutions through the ParetoHealth Pharmacy Consortium. By pooling employers into a single risk pool, ParetoHealth enhances negotiating leverage and risk stabilization, allowing midsize businesses access to cost-saving tools typically available to larger corporations.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
For over 120 years, Parr Instrument Company has been designing, manufacturing, and selling high quality laboratory instruments and apparatus for conducting chemical reactions and tests under heat and pressure and for testing fuels. Parrs extensive product line includes stirred reactors, pressure vessels, and high pressure tubular reactors for the study of catalytic and non-catalytic reactions in batch, continuous-flow, and multiple/parallel operation for the chemical, polymer, biofuels, hydrometallurgical, pharmaceutical, petroleum, and petrochemical industries. Custom designed complex reactor systems, built to the customers specifications and requirements are also provided. Parrs oxygen combustion calorimeters are used for the determination of the heat of combustion in solid, liquid, and refuse-derived fuels for the energy, educational, coal, and fuel testing industries. Parr also offers sample preparation vessels for extraction, digestion, and hydrothermal synthesis, as well as a line of vessels for cell disruption by nitrogen decompression.